Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 4/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 7/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17870725 | 0.82 | GAA (0.47) | GAAKMT2A | |
| SCHEMBL21900227 | 0.80 | MAPT (0.46) | GAAMAPTALDH1A1 | |
| SCHEMBL19873713 | 0.79 | GAA (0.47) | GAAALDH1A1 | |
| SCHEMBL19873897 | 0.79 | GAA (0.42) | GAAPABPC1KMT2AMAPTALDH1A1 | |
| SCHEMBL28652312 | 0.79 | KDM4E (0.48) | GAAKMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL21900257 | 0.78 | GAA (0.46) | GAAPABPC1KMT2AMAPTALDH1A1 | |
| SCHEMBL28639201 | 0.77 | GAA (0.40) | GAAPABPC1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL28638741 | 0.72 | GAA (0.42) | GAAPABPC1KMT2AMAPTALDH1A1 | |
| SCHEMBL6516911 | 0.66 | APAF1 (0.45) | APAF1POLBP2RX3ALDH1A1 | |
| SCHEMBL28649422 | 0.64 | USP5 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | MC1R, CALCRL, BDKRB2 | GAA 1335/4885APAF1 3304/4885PABPC1 4692/4885 |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | MC1R, BDKRB2, CCKBR | GAA 1096/4885APAF1 3520/4885PABPC1 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.